CANY
MYOK

Caxton Associates (New York)’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Caxton Associates (New York)’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,845
Closed -$555K – 686
2020
Q1 		$555K Buy
+11,845
New +$759K 0.1% 138

Other funds holding MYOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Caxton Associates (New York)'s MYOK Position: Q2 2020 in Review

Caxton Associates (New York) sold out of MyoKardia, Inc. Common Stock (MYOK) in Q2 2020, closing a stake of 11,845 shares — an estimated $555K sold.

Caxton Associates (New York) first reported a position in MYOK in Q1 2020 and held it in 1 quarter. The position peaked at $555K in Q1 2020. 235 funds tracked by Wall St. Rank hold MYOK as of Q2 2020.

  • Caxton Associates (New York) reported no remaining MyoKardia, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,845 MyoKardia, Inc. Common Stock shares in Q2 2020, an estimated $555K.
  • Caxton Associates (New York) first reported a position in MyoKardia, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s MyoKardia, Inc. Common Stock position peaked at $555K in Q1 2020.
  • 235 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.